| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7f6e33603375c486b0ab3505830af9e8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C279-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39533
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D475-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C279-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D475-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2000-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f8720b7981e95a20d533fc7bf066ba5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b9cfc1ddaedc4611ba1523cdf5b0410
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_26113e01af1fd6cdba6d5c14b6dcab4b |
| publicationDate |
2004-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-515598-A |
| titleOfInvention |
Synergistic medicinal compositions containing anti-Fas antibody and a compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity |
| abstract |
A pharmaceutical composition comprising: a) an anti-human Fas antibody having an apoptosis inducing activity selected from CH11, HFE7A or a humanized antibody, and b) a compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity. Whereby the combination exhibits a synergistic apoptosis inducing activity. An example of a compound having a folate antagonistic activity or a dihydrofolate reductase inhibiting activity may include but not limited to methotrexate, edatrexate and brodimoprim. |
| priorityDate |
1999-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |